Drug Enforcement Administration (DEA)

The Drug Enforcement Administration is the lead federal agency for enforcing controlled substances laws. Operating within the Department of Justice, the DEA investigates drug trafficking organizations, enforces the Controlled Substances Act's regulatory framework (scheduling, registration, manufacturing quotas), and coordinates with international partners to disrupt the global drug trade. The DEA has approximately 10,000 employees, including over 4,600 special agents, and maintains offices in all 50 states and over 90 countries.

Current Law (2026)

Legal Authority

• 21 U.S.C. § 811 — Drug scheduling authority (the Attorney General may add, remove, or reschedule substances; requires scientific and medical evaluation by HHS; 8 factors considered including abuse potential, scientific evidence, and public health risk)
• 21 U.S.C. § 812 — Schedules of controlled substances (establishes the five-schedule framework: Schedule I (high abuse potential, no accepted medical use) through Schedule V (lowest abuse potential))
• 21 U.S.C. §§ 821–824 — Registration requirements (manufacturers, distributors, dispensers, and researchers of controlled substances must register with the DEA; registration can be denied, suspended, or revoked)
• 21 U.S.C. § 841 — Prohibited acts (unlawful to manufacture, distribute, dispense, or possess with intent to distribute controlled substances except as authorized)
• 21 U.S.C. § 871 — DEA authority (Attorney General authorized to carry out enforcement, cooperate with state and local agencies, and enter cooperative arrangements)
• 21 U.S.C. § 878 — Powers of enforcement personnel (DEA agents may carry firearms, execute warrants, make warrantless arrests for drug offenses, and perform undercover operations)
• 21 U.S.C. § 846 — Attempt and conspiracy (attempting or conspiring to commit any drug trafficking offense under the CSA carries the same penalty as the completed offense — used to reach entire drug distribution networks)
• 21 U.S.C. § 848 — Continuing criminal enterprise / CCE (the "kingpin" statute: any person who organizes, manages, or supervises 5+ persons in a series of drug violations generating substantial income may be sentenced to life imprisonment and $4 million fine; required forfeiture of profits and properties)
• 21 U.S.C. § 860 — Distribution or manufacturing in or near schools and colleges (doubles otherwise-applicable penalties for drug distribution or manufacturing within 1,000 feet of a school, public housing, or playground)
• 21 U.S.C. § 881 — Forfeitures (controlled substances, raw materials, equipment, conveyances, money, and other property connected to drug violations are subject to forfeiture)

How It Works

The DEA has two distinct but interrelated functions: criminal enforcement against drug trafficking and regulatory control over legitimate controlled substances.

On the enforcement side, the DEA targets drug trafficking organizations (DTOs) at every level — from international cartels moving tons of cocaine, fentanyl, and methamphetamine into the United States to regional distribution networks and local dealers. The agency uses undercover operations, wiretaps, informants, financial investigations, and cooperation with foreign law enforcement to build cases. The DEA's Organized Crime Drug Enforcement Task Force (OCDETF) program coordinates multi-agency investigations targeting the highest-level DTOs.

The Diversion Control Division is the DEA's regulatory arm, overseeing the legitimate supply chain for controlled substances. Every entity that handles controlled substances — pharmaceutical manufacturers, distributors, pharmacies, hospitals, physicians, researchers — must register with the DEA. The DEA sets annual manufacturing quotas for controlled substances, inspects registrants for compliance, and investigates diversion (legitimate drugs entering the illicit market). The opioid crisis put a spotlight on diversion enforcement, with the DEA pursuing manufacturers and distributors who failed to flag suspicious orders.

Drug scheduling is one of the DEA's most consequential powers. When the Attorney General (through the DEA) proposes to schedule, reschedule, or deschedule a substance, the process requires HHS to conduct a scientific and medical evaluation. Eight factors are considered, including the substance's pharmacology, abuse potential, scientific evidence of effects, history of abuse, risk to public health, and whether it's an immediate precursor to a controlled substance. This process has been central to debates over marijuana reclassification, kratom scheduling, and the scheduling of fentanyl analogues.

The DEA's international operations are extensive — 93 offices in 69 countries work with foreign counterparts on intelligence sharing, investigations, and capacity building. Given that nearly all illicit drugs consumed in the U.S. originate abroad, the DEA's international presence is critical to its enforcement mission.

How It Affects You

State Variations

Implementing Regulations

• 21 CFR Part 1300 — DEA Definitions: the foundational chapter that defines every term used across DEA's entire regulatory framework — all substantive Parts (1301 through 1321) incorporate the definitions established here. Key provisions:

  • § 1300.01 — Definitions for controlled substances regulations: "administer" (direct application of a controlled substance by a practitioner to a patient), "distribute" (delivery by other than administering or dispensing — the wholesale distribution chain), "dispense" (deliver to an ultimate user pursuant to a lawful prescription — the retail pharmacy or practitioner-dispensing act), "practitioner" (physician, dentist, veterinarian, or other licensed under state law to handle controlled substances), and "valid prescription" (issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice — the definition that is central to pill mill prosecutions and corresponding responsibility enforcement)
  • § 1300.02 — Definitions for listed chemicals: "listed chemical" (precursor chemicals on Schedule I or II of the Chemical Diversion and Trafficking Act — pseudoephedrine, ephedrine, and other methamphetamine precursors that trigger Combat Methamphetamine Epidemic Act purchase limits and recordkeeping at pharmacies), "regulated transaction," and "retail distributor" (pharmacy selling to walk-in customers subject to purchase limits)
  • § 1300.03 — Definitions for electronic orders and prescriptions: defines the Controlled Substances Ordering System (CSOS — DEA's PKI-based electronic authorization system that replaced paper DEA Form 222 for ordering Schedule I/II controlled substances); defines "electronic prescription," "two-factor authentication," and the digital certificate requirements for Electronic Prescriptions for Controlled Substances (EPCS) systems — the legal underpinning for e-prescribing platforms like Surescripts
  • § 1300.04 — Definitions for Internet dispensing: defines "online pharmacy" (must be registered under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008), "in-person medical evaluation" (a face-to-face encounter — the statutory prerequisite, with narrow telemedicine exceptions, before prescribing controlled substances over the Internet), and "valid prescription" in the internet dispensing context; these definitions are the legal framework for DEA's online pharmacy enforcement and the regulatory basis for the ongoing telemedicine prescribing debate
  • § 1300.05 — Definitions for disposal: "authorized collector" (reverse distributors, retail pharmacies, and law enforcement authorized to accept controlled substance returns or patient take-back), "non-retrievable" (the destruction standard — a substance is non-retrievable when permanently altered so it cannot be recovered through ordinary means), and "ultimate user" (the patient or household member lawfully possessing a controlled substance for personal use)

  The §1300.04 definition of "in-person medical evaluation" had major practical consequences: it was the primary barrier to telehealth-based prescribing of controlled substances (particularly stimulants for ADHD and benzodiazepines) until COVID-19 emergency waivers in March 2020. DEA proposed permanent telemedicine prescribing rules in 2023 to establish post-pandemic exceptions; as of 2026, those rules remain in a contested regulatory process. The "valid prescription" definition in §1300.01 is the doctrinal foundation for prosecutions of practitioners who wrote prescriptions without legitimate medical purpose — the central charge in pill mill and opioid diversion cases.

• 21 CFR Part 1301 — Registration of manufacturers, distributors, and dispensers of controlled substances (48 sections — the complete DEA registration framework governing who must register, how to apply, grounds for denial/revocation, physical security requirements, and exemptions). Key provisions:

  • § 1301.11 — Persons required to register: every person who manufactures, distributes, dispenses, imports, or exports a controlled substance must be registered with DEA, unless specifically exempted; DEA registration is the legal gateway for all legitimate controlled substance handling — without it, possession and distribution are criminal even for licensed healthcare providers
  • § 1301.12 — Separate registrations for separate locations: a DEA registration is location-specific; a hospital system or pharmacy chain with multiple sites must obtain a separate registration for each physical address; a practitioner who dispenses from both a clinic and a hospital must register both locations
  • § 1301.13 — Application requirements: DEA Form 224 for practitioners and researchers; Form 225 for manufacturers, distributors, and importers/exporters; registration periods are 3 years for most registrants; fees range from $888 for practitioners (2024) to higher amounts for manufacturers; online registration through DEA's Diversion Control Division portal at DEA.gov
  • § 1301.22 — Exemption for agents and employees: individual employees and agents of a registrant (e.g., a nurse who administers controlled substances under a physician's order, a warehouse worker who handles a distributor's inventory) do not need separate DEA registrations; their activities are covered by the employer's registration
  • § 1301.24 — Law enforcement exemption: DEA agents and authorized law enforcement personnel acting in their official capacity do not require DEA registrations for controlled substance handling in the course of enforcement activities
  • § 1301.28 — Buprenorphine/methadone practitioners: practitioners who prescribe or dispense Schedule III-V controlled substances approved for addiction treatment (buprenorphine/Suboxone for opioid use disorder) are eligible for a registration modification rather than a separate DEA number; the Mainstreaming Addiction Treatment (MAT) Act of 2023 eliminated the separate "X-waiver" that previously required an additional DEA registration for buprenorphine prescribing — now any DEA-registered practitioner with prescribing authority may prescribe buprenorphine for OUD up to their DEA registration authority
  • § 1301.35 — Certificate of registration and denial: DEA issues a certificate of registration upon approval; DEA may deny registration if the applicant's registration would be "inconsistent with the public interest" — a standard that considers state licensing, compliance history, and criminal record; Schedule I researcher registrations require additional showing of need and protocol review
  • § 1301.36 — Suspension or revocation: DEA may suspend or revoke a registration on findings that the registrant has materially falsified an application, been convicted of a felony relating to controlled substances, or had a state license revoked; DEA may immediately suspend (without hearing) if it finds the registrant poses an imminent danger to public health or safety — the emergency action used in high-profile opioid diversion cases against pain clinics and "pill mills"
  • § 1301.51 — Modification of registration: a registrant may modify their registration to add drug schedules or change business type without submitting a new application; modification is required when expanding into new controlled substance activities (e.g., a practitioner's clinic adding dispensing capability)

• 21 CFR Part 1302 — Labeling and Packaging Requirements for Controlled Substances: the mandatory labeling rules that make every commercial container of a controlled substance visually identifiable as such. Key provisions:

  • § 1302.03 — Schedule symbol required: every commercial container of a controlled substance must display the symbol designating its schedule — "C-I" through "C-V" (or the Roman numeral equivalent with the letter C) — prominently on the label; the symbol must appear on all labeling that accompanies the commercial container; certain excepted substances (listed under § 1308.31) are exempt from the symbol requirement; the symbol is the universal visual signal that a container holds a DEA-regulated substance
  • § 1302.04 — Symbol placement and size: the schedule symbol must be prominently placed on the principal display panel, large enough to afford easy identification by dispensers; DEA does not mandate a specific font size but the symbol must be clear and conspicuous relative to other label text — a schedule designation buried in fine print violates this requirement
  • § 1302.06 — Tamper-evident sealing: every bottle, multi-dose vial, or other commercial container of any controlled substance must have a seal affixed to the stopper, cap, lid, or covering that will disclose upon inspection any tampering or opening; this is the regulatory basis for the shrink-seal and blister-pack requirements visible on controlled substance packaging in retail pharmacies; breaking the seal, even for sampling or testing, must be documented
  • § 1302.07 — Labeling for imported and exported substances: the schedule symbol and sealing requirements apply equally to controlled substances imported into the United States; for exports, labeling must comply with both U.S. requirements and any destination-country requirements; an exported substance that does not meet destination-country labeling standards may be denied entry and return to the U.S. may require re-labeling under DEA oversight
  • § 1302.08 — False labeling of anabolic steroids: it is unlawful to import, export, manufacture, distribute, or possess anabolic steroids unless the product bears a label clearly identifying the anabolic steroid or product contained within; distributors of mislabeled anabolic steroid products face both Controlled Substances Act criminal liability and FTC/FDA enforcement for mislabeling; this provision was added when anabolic steroids were classified as Schedule III controlled substances in 1990

  The schedule symbol requirement in § 1302.03 is one of the most visible markers of the CSA's regulatory infrastructure: every prescription opioid, stimulant, benzodiazepine, and barbiturate in a pharmacy carries the "CII," "CIII," "CIV," or "CV" designation. The symbol serves both a safety function (alerting pharmacists and dispensers) and an investigative function (helping law enforcement identify controlled substances without reference to package inserts or drug databases). Counterfeit controlled substances — a major problem in the fentanyl era — typically lack compliant labeling and sealing, which is a detection indicator for DEA diversion investigators.

• 21 CFR Part 1303 — Quotas (24 sections — DEA's annual production cap system for all Schedule I and II controlled substances; the upstream supply-side control on the entire legal controlled substance market):

  • § 1303.03 — Three types of quotas: (1) Aggregate production quota (APQ) — the total quantity of each Schedule I/II substance that may be manufactured in the U.S. in a calendar year; (2) Individual manufacturing quota (IMQ) — each registered manufacturer's allocation from the aggregate cap; (3) Procurement quota — the amount a manufacturer of finished dosage forms may purchase of bulk Schedule I/II substance from another registrant for further processing
  • § 1303.11 — Aggregate production quota: DEA determines the APQ for each controlled substance by considering total U.S. medical need, scientific research use, export requirements, necessary inventory levels, and — for "covered controlled substances" since the SUPPORT Act (2018) — an estimate of the quantity being diverted to illicit use; the APQ is published in the Federal Register each year and effectively caps the total legal supply of Schedule II opioids, stimulants, and anabolic steroids available in the United States
  • § 1303.05 — Diversion estimation: the 2018 SUPPORT for Patients and Communities Act amended the CSA to require DEA to reduce the APQ for opioids and stimulants by an estimated diversion quantity, directly linking the legal supply cap to overdose data; DEA must estimate how much of the substance is being diverted from legitimate channels into illicit use and reduce the APQ accordingly
  • § 1303.13 — Mid-year APQ adjustments: DEA may increase or decrease the APQ during the year in response to changing medical need, newly identified diversion, or supply emergencies; mid-year increases require Federal Register notice; DEA used this mechanism extensively in the 2000s to increase oxycodone APQs, a decision that became central to opioid litigation
  • § 1303.21–1303.23 — Individual manufacturing quotas: issued to each registered manufacturer by December 1 of the prior year; manufacturers must apply by May 1 each year on DEA Form 189; DEA allocates based on each applicant's prior-year net disposal, estimated current-year demand, and existing inventory; manufacturers who did not need their full prior allocation receive reduced future allocations unless they document increased need
  • § 1303.25 — Mid-year IMQ increases: manufacturers may petition for additional quota during the year if unexpected demand exceeds their allocation; DEA approves if aggregate headroom remains and the request is supported by documented orders; this mechanism came under scrutiny as plaintiffs in opioid litigation argued that manufacturers obtained quota increases while ignoring diversion signals

  The DEA quota system is the supply-side control on every legal controlled substance. Every legally manufactured opioid tablet, fentanyl patch, and Adderall capsule in the United States originates within a DEA aggregate quota allocation. The system became deeply controversial during the opioid epidemic — DEA repeatedly increased oxycodone and hydrocodone APQs through the mid-2010s even as overdose deaths rose; since 2017, DEA has sharply reduced opioid APQs as prescribing declined and as DEA faced congressional scrutiny over its failure to use quota authority to constrain the epidemic.

• 21 CFR Part 1304 — Records and reports (§§ 1304.24, 1304.25 — records for maintenance treatment programs, compounding narcotic treatment programs)

• 21 CFR Part 1305 — Orders for Schedule I and II controlled substances (§§ 1305.04, 1305.06 — persons entitled to order and fill orders)

• 21 CFR Part 1312 — Importation and Exportation of Controlled Substances (31 sections — the permit system for cross-border movement; no import or export of Schedule I/II controlled substances may occur without advance DEA authorization):

  • § 1312.11 — Import permit requirement: no person may import any Schedule I or II controlled substance — or any narcotic listed in Schedule III, IV, or V — without a DEA import permit (DEA Form 35); non-narcotic Schedule III-V substances may instead use the simpler import declaration (DEA Form 236)
  • § 1312.13 — Permit issuance criteria: DEA may authorize importation only if (1) the substance is needed for legitimate U.S. medical, scientific, or industrial purposes; (2) the aggregate import quota (set under Part 1303's APQ framework) is not exceeded; and (3) total supply — domestic production plus imports — will not be more than adequate for legitimate needs; DEA transmits a copy of every import permit to the competent authority of the exporting country (implementing U.S. treaty obligations under the Single Convention on Narcotic Drugs)
  • § 1312.16 — Permit expiration: import permits are valid for no more than 180 days from issuance; unused permits expire and must be returned to DEA; a shipment received in greater quantity than authorized requires DEA notification within 5 days
  • § 1312.21 — Export permit requirement: no person may export any Schedule I or II controlled substance, or any narcotic, without a DEA export permit (DEA Form 161); the permit must be obtained before shipment; retroactive permits are not available
  • § 1312.23 — Export permit issuance: DEA approves only exports to countries with adequate controls; DEA may deny if the destination country has excessive existing stocks, inadequate regulatory controls, or if the shipment presents a diversion risk; each permit covers a single shipment to a single named consignee
  • §§ 1312.27–1312.30 — Reexport controls: when a U.S.-origin controlled substance exported to one country is re-exported to a third country, both the intermediate and final destination countries must authorize the reexport, and DEA must independently authorize the reexport of U.S.-origin substances; this requirement prevents a technique — historically used by traffickers — of routing controlled substances through permissive intermediate jurisdictions to avoid destination-country controls

  Part 1312 implements U.S. obligations under the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971) — international treaties requiring government-to-government permit exchange for all controlled substance cross-border movement. The practical significance: most opioid precursors (thebaine, codeine base derived from poppy), stimulant precursors, and research chemicals used in pharmaceutical manufacturing enter the U.S. under DEA import permits tied to the aggregate quota limits set under Part 1303 — the two systems interlock to control the entire lifecycle from foreign raw material to U.S. finished drug product.

• 21 CFR Part 1306 — DEA Prescription Requirements for Controlled Substances: the rules governing who may prescribe, how prescriptions must be written, and the specific requirements that vary by drug schedule. Key provisions:

  • § 1306.03 — Who may prescribe: only a practitioner who (1) is licensed to practice in their jurisdiction, (2) is registered with DEA (or exempt from registration), and (3) has state authority to prescribe the specific drug may issue a controlled substance prescription; a physician licensed in one state cannot prescribe to a patient in another state where the physician is not licensed, even for the same patient (though telemedicine exceptions have been created)
  • § 1306.04 — "Legitimate medical purpose" standard: this is the central prescribing rule — a controlled substance prescription is only effective if issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice; the prescriber and the pharmacist who fills the prescription both bear "corresponding responsibility" for this; a prescription issued outside the scope of treatment — including prescriptions written without adequate medical evaluation, "prescription mills," or cash-payment-only practices catering to people seeking drugs for non-medical use — violates § 1306.04 regardless of whether a DEA registration is held; the "legitimate medical purpose" standard is the primary basis for DEA criminal prosecutions of prescribers and pharmacists
  • § 1306.05 — Prescription requirements: every controlled substance prescription must be dated as of the day signed and must bear: the patient's full name and address; the drug name, strength, dosage form, and quantity; directions for use; the prescriber's name, address, and DEA registration number; and the prescriber's manual signature; Schedule II prescriptions may not be transmitted by fax to a pharmacy for dispensing (only for filing/filing purposes), with limited exceptions
  • § 1306.08 — Electronic prescriptions (EPCS): electronic prescriptions for Schedule II–V controlled substances are permitted if the practitioner's software meets DEA's technical standards for identity proofing (two-factor authentication before signing), logical access controls, and audit logging; pharmacies may accept EPCS only if their system meets DEA's pharmacy application standards; EPCS has largely replaced paper for Schedule II prescriptions in most states; DEA standards are set by 21 CFR Part 1311 (not Part 1306)
  • § 1306.09 — Online pharmacy and telehealth requirements: controlled substance prescriptions may not be issued via the Internet (including telemedicine) without a valid prescription — which the Ryan Haight Act defined as requiring at least one in-person medical evaluation; during the COVID-19 public health emergency, DEA issued temporary rules allowing prescribing via telemedicine without prior in-person evaluation for all controlled substances; in 2023–2024, DEA published proposed rules for permanent telemedicine prescribing standards; § 1306.51 (added 2024) specifically authorizes telemedicine prescribing of buprenorphine (Schedule III–V) for OUD treatment
  • § 1306.11 — Schedule II prescription requirement (NO REFILLS): a pharmacist may dispense a Schedule II controlled substance only pursuant to a written (paper) or electronic prescription; no refills are permitted for Schedule II prescriptions; the prescriber may issue multiple prescriptions on the same day authorizing a 90-day supply in total (§ 1306.12(b)) — this "multiple prescription" exception allows chronic pain patients to receive a 90-day supply without a monthly office visit, but requires post-dating and specific documentation that it's appropriate to do so
  • § 1306.12 — Schedule II refill prohibition: refilling a Schedule II prescription is prohibited — each dispensing requires a new prescription; emergency oral prescriptions for Schedule II are permitted only in genuine emergencies and only until a written prescription can be furnished (within 7 days)
  • § 1306.21–1306.22 — Schedule III–V prescriptions and refills: Schedule III and IV prescriptions may be transmitted orally or in writing (and by fax), and may be refilled up to 5 times within 6 months of the original issue date; Schedule V prescriptions may be refilled as authorized by the practitioner (with the same 6-month limit for Schedule V classified as prescription drugs); once both limits expire, a new prescription is required

  Part 1306 establishes the two-tier prescription system that every patient and prescriber experiences: Schedule II drugs (opioids like oxycodone and hydrocodone, stimulants like Adderall, some anesthetics) require a new prescription every 30 days with no ability to phone in a refill, while Schedule III-V drugs (Tylenol with codeine, Xanax, Ativan, some cough preparations) can have up to 5 refills called in over 6 months. The "corresponding responsibility" doctrine — that pharmacists as well as prescribers are legally responsible for ensuring prescriptions serve a legitimate medical purpose — was at the center of opioid litigation and enforcement against large pharmacy chains for failure to reject suspicious prescriptions from known-problem prescribers.

• 21 CFR Part 1314 — Retail Sale of Scheduled Listed Chemical Products (see also Controlled Substances Act for detailed coverage)

• 21 CFR Part 1316–1321 — DEA administrative procedures and civil/criminal penalties

• 21 CFR Part 1316 — Administrative Functions, Practices, and Procedures (49 sections — the DEA's inspection authority, warrant procedures, and administrative enforcement mechanisms). Key provisions:

  • § 1316.03 — Authority to inspect: DEA inspectors may enter and inspect any "controlled premises" — premises where controlled substances are manufactured, distributed, dispensed, stored, or administered — where a registrant operates; the standard for authorized inspection is broader than a criminal search warrant
  • § 1316.04 — Limits on inspection: without written consent from the owner or operator, DEA inspectors may not review financial records, pricing data, or sales data beyond what documents controlled substance movement; the rule limits DEA inspection scope to prevent it from functioning as a general business audit
  • § 1316.07 — Warrant requirement: in almost all cases, DEA must obtain an administrative inspection warrant from a federal or state judge before conducting an inspection without consent; the warrant standard is "administrative probable cause" — the premises are subject to inspection under the Act, not probable cause of a crime
  • § 1316.08 — Consent inspections: if the registrant's owner, operator, or agent in charge gives informed consent, no warrant is required; "informed" means DEA must advise the registrant of the right to refuse; consent under duress is invalid
  • § 1316.09 — Warrant applications: submitted to any federal judge or state court judge of record, or U.S. magistrate; must demonstrate the premises are subject to the Act and normal inspection selection criteria are met
  • § 1316.12 — Refusal to permit inspection: if a registrant refuses to allow execution of a duly issued warrant, DEA may treat the refusal as grounds for revocation of registration — giving the administrative inspection mechanism significant practical force even without criminal probable cause
  • § 1316.13 — Inspection frequency: DEA intends to inspect all manufacturers of Schedules I and II controlled substances at least once every 2 years; distributors and dispensers are inspected as resources permit and based on risk indicators

  Part 1316 also governs DEA's information-sharing restrictions under the Controlled Substances Act's confidentiality provisions: § 1316.21–1316.22 define the limits on sharing DEA investigative information about individual registrants, and § 1316.22 creates a civil right of action for persons harmed by unauthorized disclosures. The inspection and administrative procedures in Part 1316 are the non-criminal counterpart to the criminal enforcement tools in 21 U.S.C. § 841; they allow DEA to identify and sanction diversion and recordkeeping violations through administrative proceedings — which can result in registration revocation, a loss of authority to handle controlled substances — without the higher proof burden of a criminal prosecution.

• 21 CFR Part 1313 — Importation and Exportation of List I and List II Chemicals: DEA's procedures for controlling the international movement of precursor chemicals that can be used to manufacture controlled substances — primarily methamphetamine precursors (ephedrine, pseudoephedrine, phenylacetic acid) and other chemicals on the DEA Schedule of Listed Chemicals. The international dimension of chemical diversion control, implementing the Chemical Diversion and Trafficking Act (21 U.S.C. § 971):

  • DEA Form 486: importers and exporters of List I or II chemicals meeting or exceeding threshold quantities must submit an import/export declaration (Form 486 or electronic equivalent) to DEA before each transaction; DEA may delay or deny the shipment if it suspects the chemical will be diverted to illicit manufacture; the advance notification system allows DEA to share intelligence with the destination country's drug enforcement agency
  • § 1313.12 — Pre-import notification: regulated persons must provide advance notice of each import of a listed chemical above the threshold quantity; the notice must identify the importer, the exporter (in the source country), the chemical, quantity, point of entry, and date of arrival; DEA has 15 days to review and may issue an import stop order if it determines the import will be diverted
  • § 1313.15 — Regular importer status: a "regular importer" designation allows legitimate chemical companies with established DEA relationships to receive expedited clearance; regular importers must demonstrate a documented history of transactions with established foreign suppliers, compliance with chemical control requirements, and DEA-registered status as an importer; the designation reduces transaction delays while maintaining DEA oversight
  • § 1313.21–1313.26 — Export controls: export of listed chemicals above threshold quantities requires DEA Form 486 filed 15 days before export; DEA notifies the destination country (if a party to applicable international agreements) before the shipment departs; if the importing country objects or DEA determines the shipment will be diverted, DEA may issue an export stop order; the system implements the United Nations Convention Against Illicit Traffic in Narcotic Drugs, which requires participating nations to notify each other of chemical shipments

  The Part 1313 framework is the supply-side drug precursor control system at the border — it explains why Mexican methamphetamine manufacturing shifted dramatically when U.S. and Mexican authorities cracked down on bulk pseudoephedrine imports from Asia; Chinese suppliers shifted to direct shipment of finished fentanyl and fentanyl analogs, which don't require precursor chemical import controls, driving the current fentanyl crisis.

• 21 CFR Part 1317 — Disposal of Controlled Substances: the DEA rules governing how controlled substances are lawfully collected and destroyed — establishing the framework for drug take-back programs, reverse distribution, and practitioner disposal. The disposal framework is central to addressing excess prescription drug accumulation in households, which the CDC and DEA have identified as a primary source of diverted prescription opioids:

  • § 1317.05 — Registrant disposal: a DEA-registered practitioner (physician, dentist, veterinarian) who wants to dispose of controlled substances in their inventory must use an authorized collector (a DEA-registered reverse distributor), transfer to another registrant authorized to receive the substances, or, for Schedule III-V substances, use mail-in disposal via DEA-approved packaging; the practitioner may not simply discard controlled substances in trash or flush them
  • § 1317.15 — Reverse distributor registration: any entity that receives controlled substances from registrants for the purpose of return or destruction must be registered as a "reverse distributor"; reverse distributors are the specialized DEA-registered entities that operate between practitioners/pharmacies and the final destruction facility; they must maintain records of all substances received and document destruction at licensed destruction facilities
  • § 1317.30 — Authorization to collect from non-registrants (the public): certain registrants — retail pharmacies, hospitals/clinics, narcotic treatment programs, and law enforcement — may be authorized to collect controlled substances from ultimate users (patients and households) and other non-registrants for destruction; this is the legal authority for pharmacy drop-box programs and law enforcement take-back events; collection sites must be maintained under DEA-specified security conditions; inner liners (tamper-evident, waterproof collection bags, § 1317.60) must be used
  • § 1317.35 — Law enforcement collection: federal, state, tribal, and local law enforcement may collect controlled substances from ultimate users at any time, not just during designated take-back events; the law enforcement collection authority is broader than authorized collector authority and enables on-demand collection from individuals
  • § 1317.65 — Take-back events: law enforcement agencies may organize periodic take-back events at which they collect controlled substances from the public; DEA's National Prescription Drug Take Back Day (held twice annually) is the most prominent example; take-back events provide a surge-capacity collection mechanism beyond the permanent drop-box infrastructure; entities collecting at take-back events must document total weight collected by schedule and submit summary reports to DEA

  Part 1317 reflects a public health and diversion control strategy: the safest disposal of excess prescription opioids, benzodiazepines, and stimulants is through the authorized collection system — not flushing (which contaminates waterways) or trash disposal (which enables diversion). DEA's biannual take-back events have collected millions of pounds of prescription drugs since 2010. The expansion of retail pharmacy drop boxes (particularly at CVS, Walgreens, and Rite Aid locations) under Part 1317 authorization has significantly expanded permanent collection infrastructure.

• 21 CFR Part 1310 — Records and Reports of Listed Chemicals and Certain Machines; Importation and Exportation of Certain Machines (16 sections — DEA's chemical diversion tracking system for List I and List II chemicals used in illicit drug manufacturing):

  DEA maintains a two-tier list of chemicals that can be used to manufacture controlled substances: List I chemicals are directly used in the synthesis of controlled substances (ephedrine and pseudoephedrine — used to make methamphetamine; red phosphorus and iodine — also meth precursors; phenylacetone — used in amphetamine synthesis; N-acetylanthranilic acid, anthranilic acid — heroin precursor synthesis); List II chemicals are used in the manufacturing process but not as direct synthesis precursors (acetone, ethyl ether, toluene, hydrochloric acid — widely used industrial solvents that are difficult to control but which traffickers use to extract and purify drugs). The Chemical Diversion and Trafficking Act (21 U.S.C. §§ 971–980) established this control framework; Part 1310 implements it.

  • § 1310.02 — Substances covered: the listed chemicals are specified in the regulation with CAS numbers; DEA can add chemicals by rulemaking when it determines a chemical is being diverted for drug production; the list has grown significantly since meth became the primary driver — a 2026 amendment (91 FR 11455) updated the list to reflect current trafficking patterns
  • § 1310.03 — Record-keeping obligations: any regulated person who engages in a regulated transaction (manufacturing, selling, distributing, importing, exporting, or receiving at retail) involving a listed chemical must keep records; records must include the date, quantity, and form of chemical, and the identity of the other party to the transaction; records must be kept 2 years for List I and 4 years for List I retail transactions (§ 1310.04)
  • § 1310.05 — Reports to DEA: regulated persons must report to DEA when a transaction is "suspicious" — when the quantity involved is unusually large, the proposed use does not make sense, the purchaser seems unfamiliar with the chemical or its legitimate uses, the purchaser wants to pay cash for a large order, or other indicators of diversion; reports go to the Special Agent in Charge of the relevant DEA division office; this suspicious activity reporting obligation is the operational equivalent of anti-money-laundering SARs in the banking system
  • § 1310.07 — Proof of identity: regulated persons must verify the identity of all parties to listed chemical transactions; for List I chemicals at retail, photo identification is required and the seller must record the buyer's name, address, and document number
  • § 1310.08 — Excluded transactions: retail transactions in List II chemicals sold in normal commercial quantities, and certain drug products distributed under FDA approval, are excluded from regulation unless DEA specifically removes the exclusion based on diversion evidence (§ 1310.10)

  Part 1310 is the backbone of the Combat Methamphetamine Epidemic Act (2005), which removed pseudoephedrine from open shelves nationwide and required behind-the-counter sale with ID verification and quantity limits (the "Sudafed behind the counter" rule). Part 1310 records are used by DEA and state law enforcement to identify bulk chemical purchasers, trace diversion networks, and build trafficking prosecutions. The National Precursor Log Exchange (NPLEx) — a real-time point-of-sale tracking system — operates in conjunction with Part 1310 requirements in most states, blocking purchases that exceed monthly limits or flagging purchasers with prior drug records.

• 21 CFR Part 1318 — Controls to Satisfy the Requirements of the Act Applicable to the Manufacturing of Marihuana (7 sections — DEA's registration and control framework for federally authorized cannabis cultivators):

  Under the Controlled Substances Act, cannabis remains a Schedule I controlled substance. However, DEA has authority to register manufacturers to grow cannabis for federally authorized purposes — primarily for research, reference standards, and the University of Mississippi program that historically supplied research-grade cannabis to NRC-authorized researchers. Part 1318 governs these registrations.

  • § 1318.03 — Registration standard: DEA may grant a registration to manufacture cannabis (including cultivation) consistent with 21 U.S.C. § 823(a); the Administrator must consider public interest factors including the necessity of the registration to scientific research or to maintain an adequate supply for legitimate medical and scientific purposes, and the applicant's compliance record
  • § 1318.04 — Specific controls for cultivators: registered cultivators must implement physical security measures (secure perimeter, access control, video surveillance), maintain a tracking system for plants from seedling through harvest, perform accurate inventory at defined intervals, and report losses or thefts to DEA; only the exact registered quantities may be cultivated — no excess production
  • § 1318.06 — Pricing for DEA purchase/sale: when DEA or a federal agency purchases cannabis from a registered manufacturer, pricing must be determined to recover full costs and account for fair market value; DEA has historically maintained a single-source manufacturer (University of Mississippi for decades) for the federal research supply, though this monopoly was challenged by researchers as limiting research variety and quality; DEA opened registration to additional manufacturers in 2021

  Part 1318 gained policy attention in 2021–2024 as Congress debated federal cannabis reform. If cannabis were rescheduled to Schedule III (as proposed by the Biden administration in 2024) or descheduled entirely, Part 1318's registration framework would need fundamental revision — or elimination. The DEA's 2024 proposal to reschedule cannabis to Schedule III (89 FR 44597, May 2024) would significantly change the regulatory landscape for manufacturers and researchers, though the rescheduling remained pending as of May 2026. Recent rulemaking: 86 FR 54965 (October 2021) — DEA authorized additional cannabis cultivators for research supply beyond the University of Mississippi monopoly.

Pending Legislation

• HR 6103 — Exempt DEA forensic lab personnel from hiring freezes and workforce cuts. Status: Introduced.
• HR 7413 — Temporary direct-hire authority for DEA roles FY2027-2034. Status: Introduced.

Recent Developments

The fentanyl crisis has dominated DEA enforcement priorities, with synthetic opioids — primarily manufactured in Mexico using Chinese precursor chemicals — causing the majority of U.S. drug overdose deaths. The DEA has aggressively targeted fentanyl trafficking networks and pushed for permanent scheduling of fentanyl analogues. Marijuana rescheduling from Schedule I to Schedule III has been proposed but remains in process, reflecting the ongoing tension between federal scheduling and state legalization. The DEA has also focused on the online sale of controlled substances and the role of social media in drug distribution.

In March 2026, the DEA finalized the designation of propionyl chloride as a List I chemical under the Controlled Substances Act, as the chemical is used in the illicit manufacture of fentanyl and fentanyl analogs. Separately, Sigma Aldrich Research Biochemicals Inc. applied for registration as a bulk manufacturer of controlled substances.